Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Adaptimmune (ADAP) and TCR2 (TCRR) to Merge
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Webinar Series to Support Women R&D Leadership in Biotech Announced
Share Article
The Conference Forum announced a new four-part webinar series to support women R&D leadership in biotech from May 12 through August 26, 2021, virtually.
“We are delighted to bring this webinar series to help support women R&D leaders in biotech and to encourage greater equity in biotech leadership,” Valerie Bowling, Executive Director, the Conference Forum. NEW YORK (PRWEB) April 23, 2021 The Conference Forum announced a new four-part webinar series to support women R&D leadership in biotech from May 12 through August 26, 2021, virtually.
The first webinar will address navigating unconscious bias in the workplace. Panelists Ramani Varanasi of X-Biotix Therapeutics, Patricia Kitchen of Ocular Therapeutics, Dr Alison Schechter of Axcella, and Laurie Halloran of Halloran Consulting Group will discuss the realities of unconsciou
MedCity News
Getting the right data to doctors is next hurdle for precision medicine
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
Shares0
The science is getting sharper and the barriers to reimbursement are eroding. But another major obstacle remains to delivering on the promise of precision medicine.
It involves getting the right information into the hands of front-line doctors in a way that they can use it, experts and entrepreneurs in the field said in a series of interviews with MedCity News.